In March 2023, our leading compound KIT-13 was granted Rare Pediatric Disease Designation from US FDA for treatment of Rett syndrome
In March 2023, our leading compound KIT-13 was granted Orphan Drug Desigmation from US FDA for the treatment of Rett syndrome
In April 2023, NeuroCores is incorporated as a subsidiary of the Japanese prestige research institution, the Institute of Rheological Functions of Food
Informative video about Plasmalogen and its application to Alzheimer's and DementiaCheck out this great video
Copyright © 2024 Neurocores - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.